Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 3Recruiting 3Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 1774Neoplasms 1501Carcinoma, Non-Small-Cell Lung 1043Prostatic Neoplasms 957Colorectal Neoplasms 878Lung Neoplasms 800Pancreatic Neoplasms 572Carcinoma, Hepatocellular 542Leukemia, Myeloid, Acute 541Stomach Neoplasms 512Ovarian Neoplasms 507Neoplasm Metastasis 496Multiple Myeloma 495Recurrence 413Melanoma 386Squamous Cell Carcinoma of Head and Neck 370Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 355Esophageal Neoplasms 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Lymphoma 305Endometrial Neoplasms 304Triple Negative Breast Neoplasms 299Glioblastoma 298Rectal Neoplasms 280Urinary Bladder Neoplasms 264Sarcoma 264Hematologic Neoplasms 264Colonic Neoplasms 254

Interventions

pyrotinib 1pertuzumab 1disitamab vedotin 1Trastuzumab 1RC48 antibody 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Metastatic Breast Cancer × Clear all
NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting
87 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡